Adrecizumab - Adrenomed

Drug Profile

Adrecizumab - Adrenomed

Alternative Names: HAM 8101

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adrenomed
  • Class Monoclonal antibodies
  • Mechanism of Action Adrenomedullin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Septic shock

Most Recent Events

  • 11 Dec 2017 Phase-II clinical trials in Septic shock in France, Belgium, Germany, Netherlands (IV)
  • 11 Dec 2017 Adrenomed plans a proof-of-concept phase II trial for Heart-failure in 2018
  • 25 Sep 2017 Adrenomed plans the phase II ADR-02 trial for Septic shock in fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top